🇺🇸 polyene phosphatidylcholine in United States

142 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Hepatic Function Abnormal — 22 reports (15.49%)
  2. Drug-Induced Liver Injury — 20 reports (14.08%)
  3. Aspartate Aminotransferase Increased — 15 reports (10.56%)
  4. Platelet Count Decreased — 15 reports (10.56%)
  5. Alanine Aminotransferase Increased — 14 reports (9.86%)
  6. Lymphocyte Count Decreased — 14 reports (9.86%)
  7. Anaemia — 11 reports (7.75%)
  8. White Blood Cell Count Decreased — 11 reports (7.75%)
  9. Blood Glucose Increased — 10 reports (7.04%)
  10. Drug Interaction — 10 reports (7.04%)

Source database →

Other Hematology approved in United States

Frequently asked questions

Is polyene phosphatidylcholine approved in United States?

polyene phosphatidylcholine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for polyene phosphatidylcholine in United States?

Institute of Hematology & Blood Diseases Hospital, China is the originator. The local marketing authorisation holder may differ — check the official source linked above.